Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | CTSC | P53634 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 3/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5501854 | 0.81 | TRPA1 (0.52) | ESR1ESR2KMT2AALDH1A1MEN1 | |
| SCHEMBL10585788 | 0.81 | CTSC (0.49) | SLC6A4SLC6A2SLC6A3CTSCESR1 | |
| SCHEMBL353200 | 0.80 | TRPA1 (0.48) | CTSCKMT2ACYP1A2MAOB | |
| SCHEMBL5908167 | 0.79 | SLC6A4 (0.44) | SLC6A4SLC6A2SLC6A3CTSCESR1 | |
| SCHEMBL11302551 | 0.78 | CTSC (0.47) | SLC6A4SLC6A2SLC6A3CTSCCYP2C9 | |
| SCHEMBL31648126 | 0.77 | DPP4 (0.40) | KMT2APPARGPPARADPP4FAP | |
| SCHEMBL18703964 | 0.76 | SLC6A4 (0.48) | SLC6A4SLC6A2SLC6A3CTSCESR1 | |
| SCHEMBL4657515 | 0.75 | SLC6A4 (0.52) | SLC6A4SLC6A2SLC6A3CTSCESR1 | |
| SCHEMBL8922306 | 0.74 | CTSC (0.41) | SLC6A4SLC6A2SLC6A3CTSCCYP1A2 | |
| SCHEMBL6153738 | 0.73 | SLC6A4 (0.54) | SLC6A4SLC6A2SLC6A3KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3898633-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2021-10-27 | — | — | EP | disclosed |
| CN-113474348-A | Substituted oxopyridine derivatives | 拜耳公司 | 2021-10-01 | — | — | CN | disclosed |
| WO-2020127504-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020127504-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-06-25 | — | — | WO | disclosed |
| US-9303040-B2 | Substituted piperazines as AKT inhibitors | ARRAY BIOPHARMA INC. (US) | 2016-04-05 | — | — | US | disclosed |
| CN-101516891-B | Dihydrothieno pyrimidines as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC | 2013-06-05 | — | — | CN | disclosed |
| US-20120329808-A1 | DIHYDROTHIENO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-12-27 | — | — | US | disclosed |
| EP-2054418-B1 | DIHYDROTHIENO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2011-11-09 | — | — | EP | disclosed |
| EP-2054418-A1 | DIHYDROTHIENO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008006039-A1 | DIHYDROTHIENO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329808-A1 | DIHYDROTHIENO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | DTYMK, TK1, PIK3CA | SLC6A4 2442/4885SLC6A2 3114/4885SLC6A3 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.